My Screeners
No screeners
System Screeners
My Watchlists
No watchlists
System Watchlists
Loading...
ABIONYX Pharma is a French biotechnology company focused primarily on developing novel biotherapeutics for sepsis and critical care, leveraging its proprietary platform built around recombinant apoA-I (apolipoprotein A-I) and HDL-based vectors. Its lead product candidate, CER-001, comprises recombinant human apoA-I complexed with specific phospholipids, mimics nascent HDL, and is designed to ameliorate immune-inflammatory dysregulation. CER-001 is under development in multiple therapeutic indications including sepsis, lecithin cholesterol acyltransferase (LCAT) deficiency, and Norum disease, and has progressed through preclinical studies, a Phase I trial in healthy volunteers, and further Phase 2a clinical studies. The company has obtained orphan drug designation from the U.S. Food and Drug Administration for CER-001 in treating LCAT deficiency.
In addition to its therapeutic development programs, ABIONYX Pharma operates a subsidiary, IRIS Pharma, which provides contract research organization (CRO) services specializing in ophthalmology. In its most recent financial reporting, all its revenue derives from these CRO activities; its therapeutic programs currently do not generate commercial income, though CER-001 is provided free of charge under Compassionate Use Authorizations in rare disease settings. The company has also established an exclusive global strategic partnership with SEBIA to jointly develop diagnostic tests for earlier detection and monitoring of sepsis severity.
ABIONYX Pharma is headquartered in Balma, in the Occitanie region of France, and maintains operations in France and the United States. Its technology platform entails bioproduction of recombinant apoA-I and synthetic phospholipids (notably sphingomyelin), including recent achievement of fully synthetic sphingomyelin to enhance batch consistency and safety. The company secures financial support through CRO revenues, government grants (including via France's France-2030 plan), and recent capital raises and non-dilutive instruments, enabling its financial visibility through 2028.
Click to see warnings
Effective scoring profile: Standard company
Remaining score inputs are provider supplied.
Log in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see financial data
Log in for full accessIt is important that you understand how Findx arrives at Fair Value. Please take a minute to watch this short explainer.
It is very important that you understand this
Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.